We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

Fund managers haven’t disclosed any holdings of VNDA yet.

VNDA Hedge Fund Activity: Q1 2026 in Review

170 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2026, worth a combined $319M — down 14% from $369M a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new VNDA positions and 28 closed out — a net gain of 21 holders — while 63 added to existing stakes and 38 trimmed.

The largest buyer was State Street, adding an estimated $13.5M. The largest seller was Acadian Asset Management, cutting an estimated $4.74M.

  • 170 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2026, up from 153 in Q4 2025.
  • Funds reported $319M of Vanda Pharmaceuticals stock for Q1 2026, down 14% quarter-over-quarter.
  • 49 funds opened new Vanda Pharmaceuticals positions in Q1 2026 and 28 closed out, a net change of +21 holders.
  • The largest Vanda Pharmaceuticals buyer in Q1 2026 was State Street, an estimated $13.5M added.
  • The largest Vanda Pharmaceuticals seller in Q1 2026 was Acadian Asset Management, an estimated $4.74M sold.

Based on aggregated 13F filings for Q1 2026.